EVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Evotec SE is not a strong buy for a beginner investor with a long-term strategy at this time. The technical indicators are bearish, financial performance shows declining revenue and negative margins, and there are no significant positive catalysts or strong trading signals. It is better to hold off on investing in this stock until there are clearer signs of recovery or growth.
The technical indicators are bearish. The MACD is negative and expanding downward, RSI is neutral at 37.171, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 3.594, with key support at 3.426 and resistance at 3.762.
NULL identified. There are no recent news or significant positive trading trends, and the stock lacks strong AI or SwingMax trading signals.
The MACD and moving averages suggest a bearish trend. Analysts' ratings and price targets do not provide strong upward momentum for the stock.
In Q3 2025, revenue dropped by -5.70% YoY to $191.55M. Net income improved slightly but remains negative at -$50.36M (+15.65% YoY). EPS increased to -0.28 (+12.00% YoY), but gross margin declined significantly to -0.04 (-100.40% YoY), reflecting poor profitability.
Berenberg recently initiated coverage with a Buy rating and a EUR 10 price target, citing the company's leading position in drug discovery and favorable market trends. However, there are no consistent upgrades or strong positive sentiment from other analysts, and recent analyst activity for similar companies shows mixed or negative sentiment.
